Telithromycin. Fresh from the Pipeline
Nature Reviews Drug Discovery
In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?
Raja, Aarti; J. Lebbos; and P. Kirtpatrick. 2004. "Telithromycin. Fresh from the Pipeline." Nature Reviews Drug Discovery , (). https://nsuworks.nova.edu/cnso_bio_facarticles/71